Augmentation with Buspirone: A Review
Annals of Clinical PsychiatryPublished 1 September 1995
Kenneth Harvey, Richard Balon
Citations30
SJR quartileQ3
SJR score0.39
SNIP0.54
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
This work reviews the literature supporting the potential use of buspirone as an augmenting agent and indicates that it may prove to be a useful agent for augmentation of other psychotropic medications in these disorders.
Abstract
Buspirone, an azaspirone serotonin (5-HT) 1A partial agonist, has been approved by the FDA as an anxiolytic. It has been tested for use in depression, panic disorder, obsessive-compulsive disorder, and schizophrenia as well. Several trials have indicated that it may prove to be a useful agent for augmentation of other psychotropic medications in these disorders. We review the literature supporting the potential use of buspirone as an augmenting agent.
Keywords
PsychologyNeuroscience
PubMedBuspirone and diazepam in anxiety: a controlled study.
308 Citations1982Karl Rickels, K Weisman +5 more
Those who improved most were married, well-educated females who had both a positive family adjustment and a low level of depression, while buspirone appears more effective in reducing symptoms associated with cognitive and interpersonal problems.
PubMedBuspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
147 Citations1991James E. Mitchell, Sheila Specker +1 more
Most patients with bulimia evidence metabolic and endocrine changes suggestive of a state of semistarvation, and a careful physical assessment is indicated for each bulimic patient.
American Journal of PsychiatryLimited therapeutic effect of addition of buspirone in fluvoxamine- refractory obsessive-compulsive disorder
127 Citations1993Christopher J. McDougle, Wayne K. Goodman +6 more
The authors found that buspirone added to the treatment of 33 patients with obsessive-compulsive disorder who were refractory to the serotonin reuptake inhibitor fluvoxamine was no better than placebo in reducing obsessive-Compulsive, depressive, or anxiety symptoms.
American Journal of PsychiatryDouble-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder
120 Citations1993T.A. Grady, Teresa A. Pigott +4 more
In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each and there were no significant differences in obsessive-Compulsive, depressive, or anxiety symptoms.
Current Opinion in CardiologyA Double-Blind Study of Adjuvant Buspirone Hydrochloride in Clomipramine-Treated Patients with Obsessive-Compulsive Disorder
116 Citations1992Teresa A. Pigott, F L'Heureux +4 more
It is suggested that adjunctive buspirone therapy is not generally associated with significant further clinical improvement in OCD or depressive symptoms compared with clomipramine monotherapy, but that there may be a subgroup of patients who do benefit from adjuvant buspir one therapy.
American Journal of PsychiatryControlled comparison of buspirone and clomipramine in obsessive- compulsive disorder
108 Citations1991Michele T. Pato, Teresa A. Pigott +4 more
Eighteen outpatients with obsessive-compulsive disorder were treated with either buspirone, a partial serotonin agonist, or clomipramine, a serotonin uptake inhibitor, in a double-blind, random-assignment study and both drugs led to statistically significant and similar improvements in scores on the Yale-Brown Obsessive-Compulsive Rating Scale.
Journal of Clinical PsychopharmacologyAn Open Trial of Buspirone Added to Neuroleptics in Schizophrenic Patients
98 Citations1991Donald Goff, Kamal K. Midha +4 more
Twenty chronic schizophrenic patients completed at least 2 weeks of a 6-week trial of buspirone added to a stable dose of neuroleptic, and mean scores were significantly improved on the Brief Psychiatric Rating Scale, the Simpson Angus Scale for Extrapyramidal Symptoms and the Global Assessment Scale.
PubMedBuspirone in major depression: a controlled study.
83 Citations1991Karl Rickels, Jay D. Amsterdam +3 more
Buspirone was found to be safe and well tolerated at doses of up to 90 mg/day, and treatment response to buspirone significantly better than to placebo at treatment endpoint.
PubMedPossible augmentation of antidepressant response by buspirone.
82 Citations1991Frederick M. Jacobsen
Results suggest that low doses of buspirone may be useful in augmenting antidepressant response and that patients who suffered winter relapses of depression while receiving previously effective antidepressant regimens showed remission of depressive symptoms after the addition of busPirone 10 mg t.i.d.
PsychopathologySerotonergic Anxiolytics in the Treatment of Panic Disorder: A Controlled Study With Buspirone
62 Citations2010Robert Pohl, Richard Balon +2 more
Both buspirone and imipramine tended to be better than placebo on total number of panic attacks, global psychopathology, and the Hamilton Anxiety rating scale, but end point differences among treatments were not statistically significant.
Journal of Clinical PsychopharmacologyBuspirone in the Treatment of Tardive Dyskinesia
59 Citations1993Lori Moss, Vernon M. Neppe +1 more
It is suggested that relatively high doses of buspirone may be efficacious in the treatment of TD and in neuroleptic-induced extrapyramidal side effects such as parkinsonism and akathisia.
Journal of Clinical PsychopharmacologyEffects of Buspirone in Seven Schizophrenic Subjects
38 Citations1990David L. Brody, LENARD A. ABLER +3 more
Comparaison des symptomes de base et des symptome apres traitement de patients schizophreniques recevant de the buspirone en chimiotherapie.
Journal of Clinical PsychopharmacologyUse of Buspirone in the Treatment of Schizophrenia
37 Citations1989Robert Sovner, NANCY PARNELL-SOVNER
American Journal of PsychiatryAdjunctive buspirone in benzodiazepine treatment of four patients with panic disorder
36 Citations1989David R. Gastfriend, J F Rosenbaum
Four patients with panic disorder whose panic attacks responded to benzodiazepine treatment but who suffered persistent anxiety improved after addition of buspirone, suggesting it may offer an adjunctive benefit when added to Benzodiazepines in panic disorder.
PubMedOral dyskinesia associated with buspirone use in an elderly woman.
28 Citations1988A Strauss
Pronounced oral dyskinesia developed in an elderly woman with advanced dementia who had been treated with buspirone for 3 days, and at the time of the report 4 months after symptom onset, the dyskine persisted.
PubMedAcute generalized myoclonus following buspirone administration.
22 Citations1988Elspeth Cameron Ritchie, R. Harlan Bridenbaugh +1 more
A 62-year-old woman who was hospitalized with severe medical problems that included congestive heart failure secondary to mitral stenosis and atrial fibrillation, coronary artery disease, chronic renal failure, and a recent history of a right cerebral lacunar infarction is presented.
Journal of Clinical PsychopharmacologyBuspirone-Induced Hypomania
18 Citations1988Nazzareno E. Liegghio, Vikram K. Yeragani